Dysregulation of mutant ALK2: More than just loss of binding of inhibitory factors
| Main Authors: | Williams, E. P., Bullock, A. N. |
|---|---|
| Format: | Proceeding |
| Terbitan: |
, 2019
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/2640488 |
Daftar Isi:
- Poster presented at the Biochemical Society Conference: BMP Signalling in Cancer II held at St. Annes college in Oxford, April 2019. You can read more about it here on the SGC open notebook.
- Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.